Min Gong, Ph.D.

Min Gong, PhD

Professor

Department of Pharmacy

Tianjin Medical University

22 Qixiangtai Road

Tianjin 300070

Phone:

Email: gongmin@tmu.edu.cn

Education

BA     Beijing University of Chemical Technology, Beijing, China, 2000

Ph.D.  University of Manchester, Manchester, UK, 2005

Postdoctoral Fellow  University of Oxford, Oxford, UK, 2008

Professional Experience

2008-2011    Assistant Professor, School of Life Sciences, University of Birmingham, UK

2011-2014    Principle Investigator, Tianjin Institute of Pharmaceutical Research, Tianjin, China

2014-2016    Assistant of Professor, Department of Oncology, University of Oxford, UK

2016-present Professor, Department of Pharmacy, Tianjin Medical University, China

Membership of Academic Society

Cancer Research Council of UK (CRUK)

Biotechnology and Biological Sciences Research Council (BBSRC, UK)

Publication

[1] Ying Li, Xuemin Zheng, Xiulin Yi, CHangxiao Liu, Dexin Kong and Min Gong. Myricetin, a small molecule of class B GPCRs receptor agonist, potent oral drug candidate for the treatment of type 2 diabetes. FASEB Journal. 2017 (Epub)

[2] Myricetin, a potent natural agent for treatment of diabetic skin damage by modulating TIMP/MMPs balance and oxidative stress. Wu Z, Zheng X, Gong M*, Li Y. Oncotarget. 2016 Sep 28

[3] Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma.Li Y, Zheng X, Gong M*, Zhang J. Oncotarget. 2016 Oct 17

[4] Huang C, Yi X, Kong D, Chen L, Min G*. Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide. Oncotarget. 2016 Jul 20

[5] Wang R, Zhang Q, Peng X, Zhou C, Zhong Y, Chen X, Qiu Y, Jin M, Gong M, Kong D. Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway. Sci Rep. 2016 May 31;6:27071

[6] Zhao L, Xu H, Li Y, Song D, Wang X, Qiao M, Gong M*. Novel application of hydrophobin in medical science: a drug carrier for improving serum stability. Sci Rep. 2016 May 23;6:26461

[7] Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M*. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Sci Rep. 2015 Dec 11;5:18039

[8] Wu W, Dong Y, Gao J, Gong M, Zhang X, Kong W, Li Y, Zeng Y, Si D, Wei Z, Ci X, Jiang L, Li W, Li Q, Yi X, Liu C. Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors. Cancer Sci. 2015 Jun;106(6):747-56.

[9] Dan Hua, Xuemin Zheng, Weiling Kong, Changxiao Liu, Lida Tang, Ying Li and Min Gong*. A potent tumor targeting drug release system comprising MMP2 specific peptide fragment and self assembling feature. Drug Design, Development and Therapy.

[10] Xue Yang, Ying Li, Xuemin Zheng, Weiling Kong, Changxiao Liu, Yazhuo Li and Min Gong*. Long-acting GLP-1 analog in V-shaped conformation by terminal poly-lysine modifications. Molecular Pharmaceutics.

[11] Mu S, Liu Y, Gong M, Liu DK, Liu CX. Synthesis and biological evaluation of substituted desloratadines as potent arginine vasopressin V2 receptor antagonists. Molecules. 2014 Feb 24;19(2):2694-706.

[12] Yazhuo Li, Lida Tang and Min Gong*., 2014. Developments of Glucagon Like Peptide-1 (GLP-1) and Preclinical Studies for Treatment of Type 2 Diabetes. Current Pharmaceutical Biotechnology, Vol.14 (9), pp.835-841.2014

[13] Li Y, Shao M, Zheng X, Kong W, Zhang J, Gong M*. Self-Assembling peptides improve the stability of glucagon-like peptide-1 by forming a stable and sustained complex. Mol Pharm. 2013, 10(9):3356-65. 2013

[14] Li, Y., Zheng, X., Cao, Z., Xu, W., Zhang, J., Gong, M*., 2012. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin. Int J Pharm 434, 209-214.

[15] Cao, Z., Li, Y., Tang, L., Xu, W., Liu, C., Zhang, J., Gong, M*., 2012. Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo. Diabetes Res Clin Pract 96, 362-370.

[16] Ying Li, Lida Tang, Weiren Xu, Min Gong* and Jianning Zhang*. A GLP-1 analogue containing Trp-cage exhibited an extended half-life in vivo. PEPTIDES.2011, 10.1016/j.peptides.2011.05.026

[17] Ying Li, Xuemin Zheng, Lida Tang, Weiren Xu and Min Gong*. GLP-1 analogs containing disulfide bond exhibited longer half-life in vivo than GLP-1. Peptides. 2011, doi:10.1016/j.peptides.2011.04.001

[18] Ying Li, Gang Fu, Ker Marshall, Lida Tang and Min Gong*. Peptide complex containing GLP-1 exhibited long-acting property in treatment of type 2 diabetes. Diabetes Research and Clinical Practice. 2011

[19] Ying Li, Gang Fu, Weiren Xu, Lida Tang and Min Gong*. GLP-1 homodimer exhibits a long-acting anti-diabetic property. Peptides. 2011 doi:10.1016/j.peptides.2011.05.003

[20] Xuemin Zheng, Ying Li, Gang Fu and Min Gong*. Application of novel peptide (Pp1) improving the half–life of exendin–4 in vivo. Peptides. 2011 doi:10.1016/j.peptides.2011.02.009

[21] Ying Li, Lida Tang, Weiren Xu, Min Gong*. A Novel Complex contained GLP-1 in Treatment of Type 2 Diabetes Compare with Liraglutide and Exenatide. Achieves of Medical Science. 2011

[22] Ying Li, Xin Li, Weiren Xu, Lida Tang, Min Gong* and Jianning Zhang*. N-terminal hairpin structure of GLP-1 analogs improved stabilization and blood glucose clearance efficiency in vivo. Diabetes Research and Clinical Practice, 2011.

[23] Zheng, X., Li, Y., Li, X., Tang, L., Xu, W., Gong, M*., 2011. Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes. Diabetes Res Clin Pract 93, 410-420.

Grant

Completed:

Research of Doxrubicin-TY805A conjugate as durg candidate for the treatment of breast cancer(2014ZX09507005-003, MOST of China)

Applicator: Min Gong, funding：1，240，000 RMB

The research of novel anti-tumor peptide (TY806A) (13RCGFSY19700, TSTC in Tianjin, China)

Applicator: Min Gong, funding：300，000 RMB